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Background: Impaired mineral homeostasis affect-
ing calcium, phosphate, and magnesium is a result of
parathyroid hormone (PTH) deﬁciency in hypopara-
thyroidism. The current standard of treatment with
active vitamin D and oral calcium does not control
levels of these major minerals. Recombinant full-
length human PTH 1–84 (rhPTH[1–84]) is being
developed for the treatment of hypoparathyroidism.
Objective: The goal of this study was to investigate
the pharmacokinetics and pharmacodynamics of a
single subcutaneous injection of rhPTH(1–84) in
patients with hypoparathyroidism.
Methods: This was an open-label, dose-escalating
study of single subcutaneous administration of 50 mg
and then 100 mg of rhPTH(1–84). Enrolled patients
(age range, 25–85 years) hadZ12 months of diagnosed
hypoparathyroidism deﬁned according to biochemical
evidence of hypocalcemia with concomitant low-serum
intact PTH and were taking dosesZ1000 mg/d of oral
calcium and Z0.25 mg/d of active vitamin D (oral
calcitriol). The patient’s prescribed dose of calcitriol
was taken the day preceding but not on the day of or
during the 24 hours after rhPTH(1–84) administration.
Each patient received a single 50-mg rhPTH(1–84) dose,
had at least a 7-day washout interval, and then received
a single 100-mg rhPTH(1–84) dose. The following
parameters were assessed: plasma PTH; serum and
urine total calcium, magnesium, phosphate, and crea-
tinine; and urine cyclic adenosine monophosphate.
Results: After administration of rhPTH(1–84) 50 mg
(n ¼ 6) and 100 mg (n ¼ 7), the approximate t½
was 2.5 to 3 hours. Plasma PTH levels increased
rapidly, then declined gradually back to predose levels
at 12 hours. The median AUC was similar with722calcitriol and rhPTH(1–84) for serum 1,25-dihydrox-
yvitamin D (calcitriol, 123–227 pg  h/mL; rhPTH[1–
84], 101–276 pg  h/mL), calcium (calcitriol, 3.3–3.7
mg  h/dL; rhPTH[1–84], 3.3–7.6 mg  h/dL), and
magnesium (calcitriol, 0.7–0.9 mg  h/dL; rhPTH[1–
84], 1.3–2.8 mg  h/dL). In contrast, the median AUC
for phosphate was strongly negative with rhPTH(1–
84) (calcitriol, 1.0 to 0.8 mg  h/dL; rhPTH[1–84],
21.3 to 26.5 mg  h/dL). Compared with calci-
triol, rhPTH(1–84) 50 mg reduced 24-hour calcium
excretion and calcium-to-creatinine ratios by 12%
and 23%, respectively, and rhPTH(1–84) 100 mg
reduced them by 26% and 27%. There was little
overall impact on urine magnesium levels. Compared
with calcitriol, rhPTH(1–84) 50 mg increased urinary
phosphate excretion and phosphate-to-creatinine ra-
tios by 53% and 54%, respectively, and rhPTH(1–84)
100 mg increased them by 45% and 42%. Urine cyclic
adenosine monophosphate–to–creatinine ratio in-
creased with rhPTH(1–84) by 2.3-fold (50 mg) and
4.4-fold (100 mg) compared with calcitriol.
Conclusions: PTH replacement therapy with
rhPTH(1–84) regulated mineral homeostasis of cal-
cium, magnesium, phosphate, and vitamin D metab-
olism toward normal in these study patients with
hypoparathyroidism. (Clin Ther. 2014;36:722–736)
& 2014 The Authors. Published by Elsevier HS
Journals, Inc. All rights reserved.Volume 36 Number 5
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INTRODUCTION
Hypoparathyroidism is a rare, complex endocrine
disorder of unbalanced mineral homeostasis resulting
from absent or inappropriately low levels of para-
thyroid hormone (PTH). The hallmark clinical pre-
sentation is characterized by hypocalcemia, although
other clinical characteristics often include hyperphos-
phatemia and may include hypomagnesemia.1–3 Cur-
rent therapy for chronic hypoparathyroidism, aimed
at controlling the symptoms of neuromuscular excit-
ability (eg, paresthesias, cramps, tetany, seizures) due
to hypocalcemia, consists of large doses of oral
calcium and active forms of vitamin D; this therapy
is designed to raise serum calcium levels by increasing
intestinal calcium absorption.4–6 Patients may need
thiazide diuretics to decrease hypercalciuria and diet-
ary phosphate restriction or binders to control hyper-
phosphatemia.4,6 These suboptimal approaches
present speciﬁc challenges for clinical care because
they are a balance between partial symptom manage-
ment and the ensuing long-term complications of soft
tissue calciﬁcations and kidney stones.4,6,7
Hypoparathyroidism is the last remaining classic
hormone deﬁciency endocrine disorder for which
replacement therapy using the native hormone has
not been approved.4,8 Initial clinical studies investi-
gated whether a synthetic truncated PTH(1–34) would
be an effective treatment.9,10 Results showed that
subcutaneous (SC) injections BID were required to
maintain normal serum calcium levels while reducing
ﬂuctuations in calcium levels and hypercalciuria.
Further improvements in the serum and urine calcium
ﬂuctuations were observed when PTH(1–34) was
delivered via a modiﬁed insulin pump.11 The effect
of treatment using full-length recombinant human
PTH (rhPTH[1–84]), which is identical to endogenous
human PTH, has been investigated.12–15 Several Phase
I/II, single-center, open-label studies demonstrated
biologic activity of rhPTH(1–84) administered as SC
injections daily or on alternate days in patients with
hypoparathyroidism.12,13 A large, randomized, pla-
cebo-controlled, Phase III registration trial (REPLACE
[Use of NPSP558 in the Treatment of Hypoparathyr-
oidism]; NCT00732615) was recently completed inMay 2014134 patients with hypoparathyroidism who received
SC injections of 50 mg/d of rhPTH(1–84), with
permitted dose escalation up to 75 mg/d and then
100 mg/d.14 Results showed that 53% of patients in
the rhPTH(1–84) group and 2% of patients in the
placebo group met the primary end point of reducing
calcium and active vitamin D doses by Z50% while
maintaining serum calcium levels above baseline.
The current study in treatment-naive patients with
hypoparathyroidism incorporated the highest and
lowest rhPTH(1–84) dose levels included in the
registration study.14 It was intended to provide
supportive pharmacokinetic (PK) and pharmaco-
dynamic (PD) data in serum and urine to better
interpret ﬁndings from other studies investigating the
use of rhPTH(1–84) as a therapy for hypopara-
thyroidism.
PATIENTS AND METHODS
Design
This was an open-label, dose-escalating, single-
dose, 2-center study. It was conducted in accordance
with the Good Clinical Practice Guidelines and the
Declaration of Helsinki. The investigational sites’
institutional review boards approved the protocol
before study initiation. Written informed consent
was obtained from patients before study participation.
The maximum enrollment was 8 male or female
(postmenopausal or nonpregnant) patients with hypo-
parathyroidism, aged 25 to 85 years, at the Mayo
Clinic (Rochester, Minnesota) and Cetero Research
(San Antonio, Texas). The main inclusion criteria
were hypoparathyroidism for Z12 months deﬁned
by hypocalcemia with concomitant serum PTH con-
centrations below the lower limit of the laboratory
normal range, doses Z1000 mg/d of oral calcium and
Z0.25 mg/d of active vitamin D (oral calcitriol), serum
magnesium levels within the normal laboratory range,
serum 25-hydroxyvitamin D (25[OH]D) levels r1.5-
fold of the laboratory upper limit of normal (ULN),
serum creatinine levels o1.5 mg/dL, and creatinine
clearance 460 mL/min. The main exclusion criteria
were hypoparathyroidism resulting from an activating
mutation in the calcium-sensing receptor gene, pseu-
dohypoparathyroidism, any non-hypoparathyroidism
disease that might affect calcium metabolism or
calcium–phosphate homeostasis, regular parenteral
calcium infusions, history of hypercalcemia and dis-
turbances in calcium and/or phosphate metabolism,723
Clinical Therapeuticsuse of diuretics within 14 days of study drug admin-
istration, calcitonin or cinacalcet hydrochloride use
within 3 months, and previous treatment with PTH(1–
84), N-terminal PTH, or PTH-related peptides or
analogues within 3 months.
rhPTH(1–84) (NPS Pharmaceuticals, Inc., Bedmin-
ster, New Jersey) was provided as a lyophilized
powder in a dual-chamber, 1-mL injection pen that
contained solution for reconstitution. Two strengths
were provided, enabling 50 or 100 μg to be recon-
stituted in 71.4 μL and directly administered as an SC
injection in the thigh by trained personnel. Each
patient received a single 50-mg rhPTH(1–84) dose
during treatment period 1, had at least a 7-day
washout interval, and then received a single 100-mg
rhPTH(1–84) dose during treatment period 2. Cal-
cium intake (dietary and supplemental) was to be held
constant throughout the study and was monitored on
the day before and up to the ﬁnal blood draw after
rhPTH(1–84) administration. Calcitriol was taken at
the patient’s prescribed dose at time 0 on day 1 but
was not taken on day 1 or during the 24 hours after
rhPTH(1–84) administration in each period. The
changes on day 1 represent the responses to each
patient’s habitual regimen of oral calcium and calci-
triol supplements. Both calcitriol (day 1) and rhPTH
(1–84) (day 1) were administered after an overnight
minimal 8-hour fast in both treatment periods. Fasting
continued 2 hours after calcitriol and rhPTH(1–84)
administration, at which time a standardized meal was
served. The protocol from day 1 was followed as
closely as possible on day 1 of each treatment period.
Assessments
Plasma PTH(1–84) levels were measured in blood
samples obtained during the 24 hours before and after
rhPTH(1–84) administration in each period by using a
whole PTH(1–84) immunoradiometric assay (Scanti-
bodies Laboratory, Inc, Santee, California). The assay
has a lower limit of quantiﬁcation of 10 pg/mL,
quantiﬁes only full-length PTH(1–84), and does not
distinguish between rhPTH(1–84) and endogenous
PTH. Baseline for each treatment period was the average
of 3 plasma samples collected during the day immedi-
ately before study drug administration (day 1). The PK
of PTH(1–84) were calculated in validated version 5.2 of
WinNonlin Enterprise (Pharsight Corporation, Cary,
North Carolina) by using noncompartmental methods
on individual concentration–time data of rhPTH(1–84).724Serum total calcium, magnesium, phosphate, and
creatinine were measured by using standard tests from
blood samples obtained during the 24 hours before
(day 1) and after (day 1) the administration of
rhPTH(1–84) in each period (the patient’s prescribed
doses of calcitriol were taken at time 0 on day 1 and
rhPTH[1–84] at time 0 on day 1). Serum 25(OH)D
and 1,25-dihydroxyvitamin D (1,25[OH]2D) levels
were determined by using LC-MS/MS. The PD pa-
rameters were calculated in WinNonlin by using
noncompartmental methods on time points relative
to the time of calcitriol (day 1) and study drug
(day 1) administration in both treatment periods. The
serum total calcium values were not albumin adjusted;
measurements of serum albumin levels indicated no
substantial changes in serum albumin concentrations
during the treatment and monitoring periods. To
assess the renal responses, urine samples were col-
lected at 0 to 3, 3 to 6, 6 to 10, 10 to 16, and 16 to
24 hours after calcitriol (day 1) and rhPTH(1–84)
(day 1) administration in each period, and the frac-
tional excretion of calcium (FECa), magnesium (FEMg),
and phosphate (FEP) were calculated, as were the
excretion of creatinine and cyclic adenosine mono-
phosphate (cAMP).
FECa, FEMg, and FEP were calculated by using the
following formula: [urine-speciﬁc mineral (mg/dL) 
serum creatinine (mg/dL)  100]/[serum-speciﬁc min-
eral (mg/dL)  urine creatinine (mg/dL)].
The safety proﬁle was monitored throughout the
study in all patients who entered the treatment phase.
Statistics
All parameters were summarized with descriptive
statistics because of the small size of the study
population.
RESULTS
Patients
PK and PD analysis for rhPTH(1–84) was per-
formed in 7 enrolled patients with hypoparathyroid-
ism; 1 additional patient was discontinued before
receiving study drug. Six patients received rhPTH(1–
84) 50 mg in period 1, and 7 patients received rhPTH
(1–84) 100 mg in period 2. The patient excluded from
the 50-mg rhPTH(1–84) analysis in period 1 had a
failed dose due to an error in use of the injection pen.
Table I summarizes patient demographic characteri-
stics and biochemistry ﬁndings at baseline. PatientVolume 36 Number 5
Table I. Patient demographic and baseline
characteristics. Unless otherwise indi-
cated, values are given as median
(range).
Characteristic Patients (N ¼ 7)
Sex, no.
Female 6
Male 1
Race (white), no. 7
Age, y 51 (39–69)
Weight, kg 78.3 (65.2–102.0)
Height, cm 163.0 (152.0–185.5)
BMI, kg/m2 28.2 (27.3–34.4)
Supplementation*
Calcium, mg/d 1500 (800–3000)
Calcitriol, mg/d 0.50 (0.50–0.75)
Serum 25(OH)D,† ng/mL
Screening 38 (22–52)
Period 1 36 (32–51)
Period 2 36 (26–43)
Serum 1,25(OH)2D,
† pg/mL
Period 1 22 (9–34)
Period 2 22 (11–45)
Serum total calcium,† mg/dL‡
Period 1 8.8 (8.4–10.8)
Period 2 8.8 (8.0–9.4)
Serum magnesium,† mg/dL
Period 1 1.6 (1.4–2.1)
Period 2 1.8 (1.5–2.0)
Serum phosphate,† mg/dL
Period 1 4.2 (3.4–5.7)
Period 2 4.4 (3.6–5.4)
Serum creatinine,† mg/dL
Period 1 1.0 (0.6–1.6)
Period 2 1.1 (0.6–1.5)
BMI ¼ body mass index; 25(OH)D ¼ 25-hydroxy-
vitamin D; 1,25(OH)2D ¼ 1,25-dihydroxyvitamin
D.
*The individual baseline daily calcium and calcitriol
doses for each patient were held constant throughout
the study, except that the calcitriol dose was reduced
from 0.75 to 0.5 mg/d in 1 patient between periods 1
and 2. The 800-mg/d dose represents the reduced dose
provided to 1 patient who had a 10.8 mg/dL serum
calcium level in period 1. To normalize the serum
calcium level, the investigator recommended an oral
dose of 800 mg/d; use of this dose resulted in the
normalization of serum calcium to 9 mg/dL in period 2.
†Reference values used by clinical laboratories for
normal range: 25(OH)D, 25 to 80 ng/mL; 1,25
(OH)2D, 18 to 72 pg/mL; serum total calcium, 8.9
to 10.1 mg/dL; serum magnesium, 1.8 to 2.5 mg/dL;
serum phosphate, 2.5 to 4.5 mg/dL; serum creatinine,
0.7 to 1.4 mg/dL.
‡One patient had an elevated baseline level in period 1,
but this level was normalized in period 2 (10.8 vs
9 mg/dL, respectively).
B.L. Clarke et al.demographics and disease characteristics at baseline
were consistent with the general characteristics of
hypoparathyroidism. Serum total 25(OH)D and
creatinine levels were within the normal range.
Serum total calcium, magnesium, and 1,25(OH)2D
levels were near the lower limit of normal, and serum
phosphate levels were at the ULN. The individual
baseline daily calcium and calcitriol doses for each
patient were held constant throughout the study (the
range for all patients is noted in Table I).
Pharmacokinetics
Baseline plasma PTH levels were below the limit of
quantiﬁcation (10 pg/mL) throughout day 1 in both
treatment periods, with the exception of 1 measure-
able concentration (11 pg/mL) in 1 patient in period 2.
After the 50- and 100-mg rhPTH(1–84) injections, a
double PTH peak was observed, with an initial peak
occurring at a median of 10 to 15 minutes and a
second peak at 1 to 3 hours (Figure 1). PTH levels
became undetectable by 12 or 24 hours. Table II
summarizes the baseline-adjusted PK parameters. The
t½ was 2.5 to 3 hours with both doses.
Pharmacodynamics
Before calcitriol administration on day 1 of each
treatment period, serum levels of 1,25(OH)2D, total
calcium, magnesium, phosphate, and creatinine were
comparable (Table I).
Serum 1,25(OH)2D
Serum 1,25(OH)2D increased promptly and peaked
at a median of 3 to 5 hours after calcitriol admin-
istration and then generally decreased and reached
baseline levels by 24 hours (Figure 2). After rhPTH(1–
84) administration, median serum 1,25(OH)2D
increased more slowly over 8 to 16 hours before
decreasing; levels remained above baseline at 24
hours. PD analysis of the baseline-adjusted serum
1,25(OH)2D proﬁles is shown in Table III. The
median maximum effect (Emax) after calcitriol or
rhPTH(1–84) administration was similar. The dif-
ference between the AUC that was above and below
the baseline value (AUCnet) was 27% higher with the
50-mg dose versus the 100-mg dose.
Calcium
The pattern of change in serum total calcium levels
was similar after both calcitriol and rhPTH(1–84):May 2014 725
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Figure 1. Plasma parathyroid hormone 1–84
(PTH[1–84]) baseline-adjusted levels
after subcutaneous injection of (A)
50 mg (n ¼ 6) or (B) 100 mg (n ¼ 7)
of recombinant human PTH(1–84)
(rhPTH[1–84]) in the thigh of
patients with hypoparathyroidism.
Values displayed are median with
minimum and maximum; the 25th
and 75th percentiles are shown by
dashed lines. The shaded area indi-
cates the lower limit of PTH quantifi-
cation. The small inset figures present
an expanded view of the time points
from zero to 3 hours.
Table II. Baseline-adjusted pharmacokinetic
parameters for parathyroid hor-
mone (1–84). Values are given as
median (range).
Parameter
rhPTH(1–84)
50 mg (n ¼ 6)
rhPTH(1–84)
100 mg (n ¼ 7)
AUC0–last,
pg  h/mL
554 (449–752) 968 (647–1087)
AUC0–1,
pg  h/mL
618 (520–822) 1117 (722–1141)
Cmax, pg/mL 175 (92–241) 189 (139–463)
Tmax, h 0.25 (0.17–2.00) 0.17 (0.08–1.50)
t½, h 2.40 (2.00–4.70) 2.96 (1.80–3.74)
CL/F, L/h 82 (61–96) 90 (88–139)
Vss/F, L 267 (221–585) 443 (253–722)
rhPTH(1–84) ¼ recombinant human parathyroid hormone
1–84; Vss/F ¼ apparent volume of distribution at steady-
state.
Clinical Therapeuticspeak levels occurred after 8 to 12 hours with calcitriol
and after 12 hours with 50 and 100 mg of rhPTH(1–84)
(Figure 3). Predose levels were not restored by 24 hours
with either treatment. PD analysis (Table III) showed
that the median Emax and AUCnet for serum total726calcium after injection of rhPTH(1–84) were com-
parable to those obtained for calcitriol admi-
nistration in the same treatment period. Unlike the
serum responses, there were marked treatment
differences in urine calcium excretion. After admin-
istration of oral calcitriol, there was an increase in
FECa followed by a plateau. In contrast, with rhPTH
(1–84), there was an immediate and substantial decrease
in FECa to a nadir in the 3- to 6-hour urine sample. Total
24-hour urinary calcium excretion and calcium-to-
creatinine ratios were similar on each day of calcitriol
treatment (Table IV). Compared with calcitriol, the
50-mg rhPTH(1–84) dose reduced 24-hour calcium
excretion and calcium-to-creatinine ratios by 12%
and 23%, respectively. The 100-mg rhPTH(1–84) dose
reduced 24-hour calcium excretion and calcium-
to-creatinine ratios by 26% and 27%.
Magnesium
Peak levels occurred with calcitriol after 5 to 12
hours (period 1) and 10 to 24 hours (period 2), and
with 50 mg of rhPTH(1–84) after 8 to 12 hours and
with 100 mg of rhPTH(1–84) after 8 to 16 hours
(Figure 4). Unlike the calcium response, serum
magnesium levels returned to baseline or lower by 24
hours after rhPTH(1–84) administration. PD analysisVolume 36 Number 5
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Figure 2. Changes in serum 1,25-dihydroxyvitamin D (1,25[OH]2D) levels after oral administration of
calcitriol or subcutaneous injection of 50 mg (n ¼ 6) or 100 mg (n ¼ 7) of recombinant human
parathyroid hormone 1–84 (rhPTH[1–84]) in patients with hypoparathyroidism. The arrows
indicate the time of treatment administration. Values displayed are median with minimum and
maximum; the 25th and 75th percentiles are shown by dashed lines.
B.L. Clarke et al.showed that, as for serum total calcium, the median
Emax and AUCnet for serum magnesium after injection
of rhPTH(1–84) were similar to those obtained for
calcitriol administration in the same treatment period,
although the highest values occurred with 100 mg of
rhPTH(1–84) (Table III). FEMg followed a pattern
similar to that observed for FECa (Figure 3), with an
initial increase in FEMg after oral calcitriol and a rapid
and marked decrease after rhPTH(1–84) admin-
istration. Total 24-hour urinary magnesium excretion
and magnesium-to-creatinine ratios were similar after
each calcitriol administration (Table IV). In contrast
to its effects on calcium excretion, rhPTH(1–84) had
little impact on overall urine magnesium, primarily
because excretion increased above predose levels in
the last 8 hours of each study day (Figure 4).
Phosphate
Calcitriol resulted in an initial small decrease in
serum phosphate levels before reaching an above-ULN
peak (12 hours), and ﬁnally a return to predose levels
(16 hours), in both periods (Figure 4). In contrast, afterMay 2014rhPTH(1–84) administration, serum phosphate levels
decreased rapidly (–1.6 mg/dL at 5 hours) to a level that
was in the lower portion of the normal range, and
thereafter progressively increased. However, baseline
levels were not restored within 24 hours with either
dose and remained at least 0.5 mg/dL below the ULN.
PD analysis found that the magnitude of the initial
decrease and the subsequent increase in serum
phosphate after calcitriol administration were similar
and resulted in an AUCnet that showed little overall
change (Table III). In marked contrast, the median Emax
for serum phosphate after rhPTH(1–84) administration
was negative because all postinjection values were
below baseline ﬁndings. The minimum effect for
serum phosphate after rhPTH(1–84) administration
was –1.5 mg/dL with both doses, and the AUCnet
values were also strongly negative. The pattern of FEP
was similar after oral calcitriol administration in both
treatment periods, with only a small increase to a level
that was generally maintained (Figure 4). In contrast,
after rhPTH(1–84) administration, FEP increased 2.6-
and 3.3-fold with 50 and 100 mg of rhPTH(1–84),727
Table III. Baseline-adjusted serum pharmacodynamic parameters in each treatment period. Values are given
as median (range).
Period 1 Period 2
Parameter
Calcitriol
(n ¼ 7)
rhPTH(1–84) 50 mg
(n ¼ 6)
Calcitriol
(n ¼ 7)
rhPTH(1–84) 100 mg
(n ¼ 7)
1,25(OH)2D
Emax, pg/mL 21.0 (8.0 to 26.0) 24.0 (7.0 to 52.0) 23.0 (–12.0 to 38.0) 17.0 (8.0 to 40.0)
AUCabove, pg  h/mL 149 (71.5 to 352) 276 (14.0 to 458) 227 (0 to 388) 120 (22.1 to 577)
AUCbelow, pg  h/mL 2.0 (0 to 29.5) 1.1 (0 to 75.5) 0 (0 to 367) 18.3 (0 to 58.1)
AUCnet, pg  h/mL 123 (69.5 to 352) 276 (–61.5 to 458) 227 (–367 to 388) 101 (–36.0 to 577)
Total calcium
Emax, mg/dL 0.7 (0.1 to 0.9) 0.7 (0.2 to 1.2) 0.7 (0.4 to 1.5) 0.9 (0.5 to 1.5)
AUCabove, mg  h/dL 4.7 (1.2 to 15.8) 4.9 (1.0 to 12.4) 4.7 (1.6 to 22.0) 7.6 (4.0 to 19.5)
AUCbelow, mg  h/dL 1.3 (0 to 7.2) 2.0 (0 to 6.9) 0.9 (0 to 2.1) 0 (0 to 2.8)
AUCnet, mg  h/dL 3.3 (–5.6 to 15.8) 3.3 (–5.4 to 12.4) 3.7 (–0.5 to 22.0) 7.6 (1.2 to 19.5)
Magnesium
Emax, mg/dL 0.1 (0 to 0.3) 0.2 (0 to 0.2) 0.1 (0.1 to 0.2) 0.2 (–0.1 to 0.4)
AUCabove, mg  h/dL 1.0 (0 to 3.7) 1.5 (0 to 2.9) 1.2 (0.2 to 3.6) 2.8 (0 to 5.4)
AUCbelow, mg  h/dL 0.3 (0 to 1.5) 0.2 (0 to 1.6) 0.1 (0 to 1.2) 0.2 (0 to 3.8)
AUCnet, mg  h/dL 0.7 (–1.5 to 3.7) 1.3 (–1.6 to 2.9) 0.9 (–1 to 3.6) 2.8 (–3.8 to 5.4)
Phosphate
Emax, mg/dL 0.4 (0.1 to 1.3) –0.3 (–0.8 to 0.1) 0.5 (0.2 to 1.5) –0.8 (–1.0 to 0.3)
Emin, mg/dL –0.7 (–1.0 to 0.1) –1.6 (–2.0 to –0.6) –0.7 (–0.8 to 0.3) –1.5 (–1.8 to –1.2)
AUCabove, mg  h/dL 1.6 (0.1 to 16.8) 0 (0 to 0.1) 3.2 (0.6 to 20.0) 0 (0 to 0.7)
AUCbelow, mg  h/dL 4.7 (0 to 8.5) 21.3 (7.3 to 35.1) 3.1 (0 to 7.7) 26.5 (10.7 to 32.9)
AUCnet, mg  h/dL –1.0 (–8.4 to 16.8) –21.3 (–35.1 to –7.3) 0.8 (–6.9 to 20.0) –26.5 (–32.9 to –10.0)
rhPTH(1–84) ¼ recombinant human parathyroid hormone 1–84; 1,25(OH)2D ¼ 1,25-dihydroxyvitamin D; Emax ¼ median
maximum effect; Emin ¼ median minimum effect; AUCabove = AUC that is above the baseline value; AUCbelow = AUC that is
below the baseline value; AUCnet ¼ difference between AUCaboveand AUCbelow.
Clinical Therapeuticsrespectively, after 3 to 6 hours compared with calcitriol
levels from 16 to 24 hours on day 1. Thereafter, FEP
after rhPTH(1–84) administration decreased progres-
sively and returned to predose levels (1624 hours).
Total 24-hour urinary phosphate excretion was in-
creased by 53% and 45% with 50 and 100 mg of
rhPTH(1–84), respectively, compared with each pre-
ceding calcitriol day (Table IV). The 24-hour urinary
phosphate-to-creatinine ratios were also increased by
54% and 42%.Calcium  Phosphate Product
At 12 hours after rhPTH(1–84) administration
(Figure 5), the time of peak serum calcium levels and728low serum phosphate levels, the calcium  phosphate
product was lower with both doses of rhPTH(1–84)
(35–36 mg2/dL2) than at baseline (41–42 mg2/dL2). In
contrast, after calcitriol administration, the calcium 
phosphate product was higher (44–46 mg2/dL2) than
baseline (39 mg2/dL2). Furthermore, a product of 55
mg2/dL2 was recorded in both periods in 1 patient and
in period 2 in a second patient at 12 hours after calcitriol
administration.Urine cAMP
In the 24 hours after calcitriol administration in both
periods, cAMP excretion was relatively stable (Figure 6).
In contrast, there was a substantial, dose-related increaseVolume 36 Number 5
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panels) of total calcium levels after oral administration of calcitriol (n ¼ 7) or subcutaneous
injection of 50 mg (n ¼ 6) or 100 mg (n ¼ 7) of recombinant human parathyroid hormone 1–84
(rhPTH[1–84]) in patients with hypoparathyroidism. The arrows indicate the time of treatment
administration. Note that the serum baseline resets to zero (horizontal dotted line) after the
24-hour calcitriol time point. Line graphs (left panels; triangles ¼ calcitriol, circles ¼ rhPTH[1–84])
of median with minimum and maximum values and the 25th and 75th percentiles are shown by
dashed lines or box and whisker plots (right panels) of median (line within box), minimum and
maximum values (ends of the lower and upper whiskers, respectively), and 25th and 75th
percentiles (top and bottom of the box).
B.L. Clarke et al.in the cAMP-to-creatinine ratio in the ﬁrst urine sample
(0–3 hours) collected after rhPTH(1–84) injection. The
urine cAMP-to-creatinine ratio increased by 2.3- and
4.4-fold with the 50- and 100-mg doses of rhPTH(1–84),
respectively, compared with the sample collected at 16
to 24 hours after calcitriol administration.
Creatinine
In the 24 hours after calcitriol administration in
both periods, median serum creatinine levels remained
constant (0.9 [range, 0.5–1.5] to 1.1 [range, 0.6–1.5]
mg/dL). In contrast, in the 12 hours after rhPTH(1–84)
administration, creatinine levels decreased progressively
from 0.9 (range, 0.7–1.6) mg/dL to 0.8 (range, 0.6–1.5)
mg/dL (50-mg dose) and from 1.0 (range, 0.7–1.5) mg/dL
to 0.9 (range, 0.5–1.3) mg/dL (100-mg dose), before
returning close to baseline levels at 16 to 24 hours. ThisMay 2014decrease correlated with increased glomerular ﬁltration
rate; median (range) creatinine clearance ﬁndings in the
3- to 6-hour samples were 125 (75–155) mL/min (50-mg
dose) and 108 (95–158) mL/min (100-mg dose), com-
pared with 91 (63–120) mL/min (calcitriol, period 1) and
92 (55–169) mL/min (calcitriol, period 2).
Safety Profile
rhPTH(1–84) was well tolerated; no serious ad-
verse events (AEs) occurred, and no patient discon-
tinued treatment because of a treatment-emergent AE.
Five of the 7 study patients reported treatment-
emergent AEs; all were deemed unrelated to study
drug by the investigators. A total of 7 of 8 AEs were
mild in severity (nausea, vessel puncture site hema-
toma, muscle strain, dysmenorrhea, tachypnea, and 2
incidents of vaginal hemorrhage in the patient who729
Table IV. Total and relative urinary excretion of calcium, magnesium, and phosphate over 24 hours after
calcitriol and recombinant human parathyroid hormone 1–84 (rhPTH[1–84]) administration.
Values are given as median (range).
Period 1 Period 2
Parameter
Calcitriol
(n ¼ 7)
rhPTH(1–84) 50 mg
(n ¼ 6)
Calcitriol
(n ¼ 7)
rhPTH(1–84) 100 mg
(n ¼ 7)
Calcium
Amount, mg 394 (130–495) 347 (86–549) 417 (145–553) 307 (125–437)
Ratio, mg/mg 0.34 (0.08–0.40) 0.27 (0.04–0.44) 0.30 (0.07–0.41) 0.22 (0.07–0.39)
Magnesium
Amount, mg 104 (58–205) 103 (52–223) 92 (64–215) 93 (59–206)
Ratio, mg/mg 0.08 (0.03–0.17) 0.08 (0.03–0.16) 0.09 (0.03–0.17) 0.09 (0.04–0.15)
Phosphate
Amount, mg 591 (247–1014) 904 (669–1278) 708 (214–1126) 1024 (685–1783)
Ratio, mg/mg 0.46 (0.21–0.72) 0.71 (0.49–0.94) 0.59 (0.24–0.81) 0.84 (0.56–1.17)
Creatinine
Amount, mg 1328 (1040–1713) 1327 (900–2021) 1287 (900–2005) 1343 (881–1700)
Ratio ¼ amount excreted normalized by creatinine.
Clinical Therapeuticsalso reported dysmenorrhea), and 1 of 8 was moder-
ate in severity (gout); however, this patient did not
receive study drug in period 1 because of an error in
using the injection pen.DISCUSSION
This study characterized the PK and the acute serum
and urine PD responses in the 24-hour period after SC
administration of 50- and 100-mg doses of rhPTH(1–
84) in patients with hypoparathyroidism. These doses
spanned those evaluated in the 24-week, Phase III
REPLACE registration study.14 The PK proﬁle was
similar to that observed in normal postmenopausal
women receiving 100 mg of rhPTH(1–84).16 Plasma
PTH levels increased rapidly, resulting in a double-
peak concentration proﬁle that was followed by a
slow decline back to predose levels at 12 hours. The
mechanism responsible for the proﬁle and extended
duration of exposure to PTH is unknown. Mean
exposure parameters with the 100-mg dose were lower
in the present study than observed previously in an
unpublished Phase Ib trial (Cmax, 233 vs 303 pg/mL;
AUC, 924 vs 1349 pg  h/mL), perhaps because the
patients in this study were heavier (median weight, 78730vs 69 kg) (data on ﬁle, NPS Pharmaceuticals, Inc.,
Bedminster, NJ; 2014).
Serum 1,25(OH)2D, total calcium, magnesium, and
phosphate levels were assessed because they are
adversely affected in hypoparathyroidism. Analysis
of urine samples across 24 hours for calcium, magne-
sium, phosphate, and cAMP provided additional
information to better understand the mechanisms
involved in the serum PD responses. A comparison
was made with PD responses after administration of
oral calcium and the active vitamin D metabolite
calcitriol during the 24-hour period preceding each
day of rhPTH(1–84) because these are normal or
habitual treatments that patients use to control
symptoms.
In this study, a comparison of the changes in serum
1,25(OH)2D levels resulting from calcitriol versus
PTH-stimulated renal 1,25(OH)2D synthesis was pos-
sible because no calcitriol was taken when rhPTH(1–
84) was administered. The 50-mg rhPTH(1–84) dose
resulted in a larger 1,25(OH)2D response than the
100-mg dose, although both peaked after 8 hours.
Renal 1-hydroxylase is regulated not only by PTH,
but its activity is also directly inhibited by cal-
cium.17,18 The higher calcium response to the 100-mgVolume 36 Number 5
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Figure 4. Changes in baseline-adjusted serum (left panels) and urinary fractional excretion (FE; right panels)
of magnesium and phosphate levels after oral administration of calcitriol (n ¼ 7) or subcutaneous
injection of 50 mg (n ¼ 6) or 100 mg (n ¼ 7) of recombinant human parathyroid hormone 1–84
(rhPTH[1–84]) in patients with hypoparathyroidism. The arrows indicate the time of treatment
administration. Note that the serum baseline resets to zero (horizontal dotted line) after the 24-
hour calcitriol time point. Line graphs (left panels; triangles ¼ calcitriol, circles ¼ rhPTH[1–84]) of
median with minimum and maximum values, and the 25th and 75th percentiles are shown by
dashed lines or box and whisker plots (right panels) of median (line within box), minimum and
maximum values (ends of the lower and upper whiskers, respectively), and 25th and 75th
percentiles (top and bottom of the box).
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Clinical Therapeuticsdose may provide a greater inhibition of enzyme
activity and, therefore, a smaller 1,25(OH)2D re-
sponse. Thus, rhPTH(1–84) produces a serum 1,25
(OH)2D response that is essentially equivalent to that
observed with calcitriol but with a delayed and
prolonged time course; peak levels occur at 8 to
9 hours after rhPTH(1–84) administration compared
with 3 hours after calcitriol administration. The
stimulation of endogenous 1,25(OH)2D formation
provides an underlying mechanism to reduce
the administration of active forms of vitamin D in
long-term treatment of hypoparathyroidism with
rhPTH(1–84).12–14,19732The greatest effects on serum calcium and magne-
sium were observed with 100 mg of rhPTH(1–84). The
increase in serum calcium levels in this study was
comparable to the response of SC rhPTH(1–84)
100 mg in normal postmenopausal women,16 with
maximum levels achieved near 12 hours. PTH has
major effects on phosphate levels, primarily by
increasing urinary excretion, and its absence in
hypoparathyroidism results in hyperphosphatemia.
Both doses of rhPTH(1–84) had profound effects on
serum phosphate, decreasing mean levels from the
upper limit to the lower quartile of the normal range
within 5 hours. The prolonged decrease in serumVolume 36 Number 5
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B.L. Clarke et al.phosphate after a single injection of rhPTH(1–84) is
consistent with the progressive decrease in phosphate
levels observed in long-term studies in patients
with hypoparathyroidism.12,13,15,20 In contrast, the
changes in serum phosphate after calcitriol adminis-
tration were considerably smaller in magnitude than
were observed with rhPTH(1–84) and were at or
above baseline levels for most of the 24 hours after
dosing. PD analysis conﬁrmed that the AUCnet for
serum phosphate after calcitriol use was small but was
strikingly negative with rhPTH(1–84). The decrease in
serum phosphate after rhPTH(1–84) administrationMay 2014resulted in a corresponding decrease in the serum
calcium  phosphate product. At 12 hours after
rhPTH(1–84) administration (the time of peak serum
calcium levels and normalized serum phosphate lev-
els), the median calcium  phosphate product was
2 to 6 mg2/dL2 lower than at baseline. In contrast,
12 hours after calcitriol administration, the calcium 
phosphate product was 5 to 6 mg2/dL2 higher than at
baseline. We were surprised to ﬁnd in 2 patients who
were taking average daily oral calcium and calcitriol
doses that the calcium  phosphate product reached a
level that is associated with an increased risk of soft733
Clinical Therapeuticstissue calciﬁcation (Z55 mg2/dL2).21 These instances
occurred at 12 to 16 hours after calcitriol admini-
stration, when peak calcium and phosphate con-
centrations are rarely measured because most blood
sampling is done in the morning.
Increased clearance of creatinine resulted in de-
creased serum creatinine levels after rhPTH(1–84)
administration. The mechanism responsible for this
increased clearance is unclear but may be related to
the vasodilatory properties of PTH resulting in in-
creased renal blood ﬂow.22,23 cAMP is an important
second messenger produced after activation of the
PTH-1 receptor, and its secretion by renal tubules is
increased after either exogenous administration of
PTH or stimulation of endogenous PTH secre-
tion.24,25 cAMP excretion increased and was maximal
at 0 to 3 hours after rhPTH(1–84) administration.
Thereafter, cAMP excretion declined in parallel with
the decrease in plasma PTH levels. As expected,
calcitriol had no effect on cAMP excretion. Measure-
ments of urinary excretion patterns of calcium, mag-
nesium, and phosphate in this study provided insights
into the mechanism underlying the changes in the
serum levels of these markers of PTH(1–84) activity.
At baseline, FECa and total 24-hour urine calcium
excretion (3% and 380 mg, respectively) were
relatively high, an expected consequence of hypopar-
athyroidism.3 FECa increased shortly after calcitriol
administration, perhaps caused in part by conco-
mitant calcium supplementation; however, there was
little overall effect on calcium excretion. In contrast,
both doses of rhPTH(1–84) decreased FECa by almost
70% within 6 hours before excretion slowly increased
again to predose levels. Total 24-hour calcium ex-
cretion was decreased by 13% and 23%, respectively,
with 50 and 100 mg of rhPTH(1–84).
Increased renal reabsorption of calcium plays an
important role in the serum calcium response to
rhPTH(1–84). Results from the PaTH study (Para-
thyroid Hormone and Alendronate for Osteoporosis
Trial) provided insights into the relative contribution
of kidney and bone to the increase in serum calcium
after administration of rhPTH(1–84).26–28 Increased
urinary calcium excretion is an important factor in the
nephrolithiasis commonly observed in hypoparathy-
roidism.3 The ability of rhPTH(1–84) to increase
serum calcium levels and, in contrast to calcitriol,
also substantially decrease urine calcium excretion is
an important observation for the potential use of734rhPTH(1–84) in patients with hypoparathyroidism.
Increased calcium retention by the body provides an
additional mechanism supporting the reduction in oral
calcium doses in the long-term treatment of hypopar-
athyroidism with rhPTH(1–84).12–14
The urinary excretion of magnesium in the present
study showed temporal patterns of changes that mir-
rored those of calcium. Although the initial decrease
of 65% in FEMg was similar to that of FECa, the
duration of the effect was shorter and FEMg actually
increased above the level observed in the previous
day’s 16- to 24-hour urine collection. This resulted in
24-hour urinary magnesium excretion after rhPTH(1–
84) being little different from calcitriol, and this
ﬁnding may play a role in the smaller serum magne-
sium response compared with calcium. Finally, quan-
tiﬁcation of urinary phosphate excretion provided a
clear explanation for the dramatic differences between
the effects of rhPTH(1–84) and calcitriol on serum
phosphate. FEP was relatively low on each day –1, an
expected consequence of hypoparathyroidism.4 Short-
term FEP increases after calcitriol are more likely to be
a consequence of food intake rather than a renal
response. In contrast, short-term rhPTH(1–84) in-
creased FEP by 43-fold before excretion returned
slowly to predose levels. Compared with excretion on
each day –1, the total 24-hour urine phosphate level
was increased by 45% to 53% after rhPTH(1–84)
administration.
Although 50- and 100-μg doses of rhPTH(1–84)
were used, the study has limitations that affect the
ability to make conclusive statements based on a
comparative analysis; the study design was a non-
randomized, single-dose administration with a 7-day
washout interval in a small population size. Despite
limitations of a relatively small number of patients,
single-dose administration, and descriptive statistics,
this study provides valuable PK and PD data after the
SC injection of rhPTH(1–84) in patients with hypo-
parathyroidism. rhPTH(1–84) was well tolerated,
with no serious AEs and no investigator-assessed
study drug–related AEs. Although baseline plasma
PTH levels were approached between 12 and
24 hours, the prolonged effects of rhPTH(1–84)
administration on serum calcium, phosphate, and
1,25(OH)2D levels provide an explanation of the
proven efﬁcacy of once-daily rhPTH(1–84) in clinical
trials in patients with an orphan disease such as
hypoparathyroidism.13,14 Moreover, the decreasedVolume 36 Number 5
B.L. Clarke et al.serum calcium  phosphate product and urine cal-
cium excretion after rhPTH(1–84) administration has
the potential to decrease the trend toward soft tissue
calciﬁcation, particularly in the kidneys, which is an
important cause of the chronic morbidity associated
with hypoparathyroidism. Thus, in contrast to stand-
ard therapy with calcitriol, PTH replacement therapy
with rhPTH(1–84) regulates mineral homeostasis of
calcium, magnesium, phosphate, and vitamin D me-
tabolism toward normal in patients with
hypoparathyroidism.
CONCLUSIONS
PTH replacement therapy with rhPTH(1–84) regu-
lated mineral homeostasis of calcium, magnesium,
phosphate, and vitamin D metabolism toward normal
in these study patients with hypoparathyroidism.
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